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Disease Management Guideline for Germany were identiﬁed.
The percentages of patients who had a switch in medications
were determined. In sub-analyses patients who were new to their
therapy and patients with concomitant (add on) medications
were also assessed. RESULTS: Compared with patients who
received the FSC, those receiving LABA+ICS were more likely to
have a switch in medication (35% versus 26%) and to use add
on medications (54% versus 35%). The highest proportion of
adequately adherent (°Y´70%) patients was among those switch-
ing between medications. About 64% of the FSC cohort showed
good adherence with an average MPR of 72%. In contrast only
15% of the patients using LABA+ICS were adequately adherent
with an average MPR of 31%. Patients continuing to take their
existing FS combination were on average 63% adherent;
however even in this group, only 48% exhibited adequate adher-
ence. The sub-analyses showed that patients who were new to
anti-asthmatic medications had the worst medication adherence
(59% for FSC; 8% for LABA+ICS). Patients with add on med-
ication (as a surrogate for severe asthma) showed a mean MPR
of 74% in the FSC and 39% in the LABA+ICS cohort. CON-
CLUSIONS: The use of the FSC combination was associated
with less treatment switching and less use of concomitant med-
ications. Furthermore the FSC cohort showed a better average
medication adherence and a higher proportion of adequate
adherent patients.
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OBJECTIVES: Population-based norms help in improving inter-
pretation of quality of life (QOL) data. The Esprint-15 ques-
tionnaire is a recently validated QoL questionnaire speciﬁc to
patients with allergic rhinitis (AR). This study was to obtain pop-
ulation reference norms for this new questionnaire. METHODS:
A cross-sectional study was carried out in primary care and spe-
cialized health care centers. The Esprint-15 questionnaire (which
has a global score and 4 dimension scores: symptoms, daily life
activities, sleep and psychological impact) was administered to a
large, heterogeneous sample of AR patients. The sample was
stratiﬁed on four characteristics (sex, age—three groups–, type
of AR—persistent and intermittent deﬁned as recommended in
the ARIA guidelines—, and symptom intensity—asymptomatic,
mild, moderate, severe). This classiﬁcation deﬁned 48 different
proﬁles of patients. Patient inclusion criteria were: over 18 years
old with a clinical diagnosis of AR, and visiting the doctor
because of AR at the time of inclusion in the study. RESULTS:
A total of 2682 AR patients were recruited: 53% women, 51%
with intermitent AR, and symptoms ranged from none or asymp-
tomatic (19%) to moderate (30%). Gender, type of AR and
symptom intensity but not age were associated with QOL scores
and were considered as stratifying variables for the reference
value tables. Mean overall score (standard deviation—SD) for
males was 2.18 (1.35) and for females 2.39 (1.37); mean (SD)
scores for patients with intermittent and persistent AR were 2.13
(1.35) and 2.47 (1.36), respectively. Reference values obtained
were organized in 29 tables, with values presented for each of
the three main variables individually and in combination via
means, standard deviations, medians, interquartile ranges and
decils. CONCLUSIONS: The reference values obtained in this
study will help to improve the interpretation of scores obtained
on the Esprint-15 questionnaire and should be useful in research
and clinical practice.
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OBJECTIVES: Ciclesonide is a novel inhaled corticosteroid (ICS)
for anti-inﬂammatory asthma therapy. Patients’ perception of
ICS-related side effects is not only important for treatment sat-
isfaction but might also have a major impact on compliance. We
used the new self-administered Inhaled Corticosteroid Ques-
tionnaire (ICQ) to compare patient-perceived side effects in a 
12-week, open-label, parallel-group study with ciclesonide or 
ﬂuticasone propionate (FP). METHODS: During the baseline
period (1–4 weeks), patients received either FP ≤ 250 μg/d (or
equivalent) or rescue medication only. Patients (n = 472, inten-
tion-to-treat population; 12–74 years) with FEV1 60–80% pre-
dicted (rescue medication) or ≥80% predicted (low dose ICS) and
deﬁned criteria for rescue medication use and asthma symptoms
were centrally randomized by IVR system to receive either 
320 μg ciclesonide once daily (ex-actuator, HFA-MDI), or 
200 μg FP twice daily (Diskus®). Patients completed the ICQ (57
questions, 7-point scale, 15 domains) at start and end of the
treatment. ICQ data were analysed by non-parametric methods
for differences between ciclesonide and FP. Intention-to-treat
analysis was of primary interest. RESULTS: After 12 weeks, the
ICQ overall score did not change signiﬁcantly in the ciclesonide
group (+0.22, p = 0.4200, two-sided), whereas statistically sig-
niﬁcantly increased (corresponding to patient-perceived worsen-
ing of the condition) in the FP group (+1.36, p = 0.0003,
two-sided). Similarly, there was no signiﬁcant change in the ICQ
domain scores in patients treated with ciclesonide, whereas with
FP signiﬁcant increases (p ≤ 0.0006, two-sided) occurred in the
domain scores “unpleasant taste” (+1.19) and “voice problems”
(+2.22). Ciclesonide was superior to FP regarding to changes in
ICQ overall score (point estimate −0.87, p = 0.0205, one-sided)
and domain score “voice problems” (point estimate −1.36, p =
0.0036, one-sided). CONCLUSION: ICS-related side-effects as
perceived by patients with moderate asthma worsened with the
relative low dose of FP 200 μg twice daily, but did not change
with ciclesonide 320 μg once daily after 12 weeks of treatment.
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OBJECTIVES: In order to measure the side effect perceptions of
patients using inhaled corticosteroids (ICS) the 57-item, 14-day
retrospective ICQ (15 domains and total score range: 0–100) was
developed. In this study we assessed the construct validity and
test-retest reliability of the ICQ in adult asthma patients.
METHODS: A total of 255 current inhaler users (non-ICS
inhaler n = 27; BDP equivalent daily low ICS dose ≤400 μg n =
61; mid dose ICS 401–800 μg n = 62; high dose ICS > 800 μg 
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n = 105) with an asthma diagnosis, reported their side effects on
the ICQ. We hypothesised that construct validity was supported
on a scale and domain level, if scores demonstrated: 1) a greater
prevalence in high dose ICS versus other dose groups for 15 ICQ
domains; 2) a dose response for the 57 items on the scale; 3)
greater convergence between local side effect domains than
between systemic and local domains of the scale; and 4) a rela-
tionship between ICS dose and ICQ scoring after adjusting for
appropriate confounders in multiple regression. Test-retest reli-
ability was measured in 71 randomly selected patients who had
no change in their medication use at day 7. The reliability of
total and domain scores were calculated between Day 1 and 7
scores, using intraclass correlation coefﬁcients (ICC). RESULTS:
All construct validity hypotheses were well supported: there was
1) greater prevalence in the high dose group; 2) a dose response
in item scoring; 3) greater convergence between local ICQ
domains; and 4) dosage group independently predicted ICQ
scoring after adjusting for confounders. The ICQ had good
reproducibility: test-retest ICC were ≥0.69 for all but one
domain. CONCLUSION: The ICQ shows good construct valid-
ity and is a reliable tool for measuring the ICS side effects per-
ceived by adults with asthma.
CARDIOVASCULAR DISEASE
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OBJECTIVES: Evaluation of peripheral vascular disease in the
primary care setting is routinely performed by contrast enhanced
magnetic resonance angiography (ce-MRA) and digital subtrac-
tion angiography (DSA). However, limited data is available on
the clinical outcomes following these diagnostic procedures.
METHODS: We identiﬁed individuals who underwent an out-
patient ce-MRA (3,444) or DSA (16,899) procedure of the lower
extremities from 1998 to 2004 in the U.S. Veterans Health care
System. Interventions (revascularization, stent, angioplasty),
amputations or mortality rates within one year of DSA or ce-
MRA were assessed, while complications within 30 days were
compared for both groups adjusted for baseline characteristics
using log-binomial regression.RESULTS: Approximately 31% of
the patients had an intervention after imaging with a greater pro-
portion having an intervention following DSA (36% vs. 20%; 
P < 0.001). Similarly, amputations (without interventions) were
more common after DSA (8% vs. 4%; P < 0.001). Mortality
within one year was comparable in both groups (6.9% vs.
6.2%). Overall complications were 2.0%, majority of the events
were vascular complications including hematomas (70.5%). Vas-
cular complications were more frequent following a DSA as com-
pared to ce-MRA (1.7% versus 0.4%). In multivariable-adjusted
models complications were lower after a ce-MRA then a DSA
procedure (RR, 0.47; 96% CI, 0.34–0.65). CONCLUSIONS:
Imaging leading to an intervention occurred only in about a third
of subjects. Overall complications rates were low but higher after
DSA. A greater understanding of clinical predictors, timing and
cost-beneﬁt of diagnostic imaging is needed to determine the best
course of action to assess and reduce the morbidity associated
with PVD.
PCV2
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OBJECTIVES: Recently published data from the second Euro
Heart Survey on Acute Coronary Syndromes (ACS) provided a
broad view of risk factors (RFs) and care pathways, but some
large countries contributed few patients to the registry. This
study was performed as a complementary analysis to describe
RFs in ACS patients undergoing percutaneous coronary inter-
vention (PCI) in 5 large European countries. METHODS: This
was a retrospective study using the IMS Health Acute Cardio-
vascular Analyzer. This is a physician-reported registry in
Germany, France, Italy, Spain, and the UK. Data collection time-
frame was January–November 2005. Use of PCI and 7 RFs asso-
ciated with poor outcomes (age was slightly modiﬁed from
Wallentin, 2005) were described by country. RESULTS: Over
400 cardiologists reported data on 8979 ACS patients. Patient
count by country was: Germany-1624, France-1654, Italy-1608,
Spain-2039, UK-2054. Including only patients who underwent
PCI and received clopidogrel (n = 4393), the frequency was
lowest in the UK (31.0%) and highest in Germany (68.8%). The
index diagnosis was: ST-elevation myocardial infarction (MI)
45%, non ST-elevation MI 29%, unstable angina 26%. Distrib-
ution of the 7 RFs was: age >65 ranged from 37.8% (UK) to
48.4% (Spain); males 67.9% (Italy) to 75.9% (France). Diabetes
ranged from 25% (France) to 35.4% (Germany). Prior MI
ranged from 9.6% (France) to 17.6% (Germany). ST-depression
occurred in 21.6% (France) to 47.3% (UK), and elevated tro-
ponin occurred in 64.4% (UK) to 80.3% (Spain). Elevated serum
creatinine occurred in 4.0% (Italy) to 10.2% (Germany). Mean
number of risk factors by country was 2.66-Germany, 2.47-
France, 2.62-Italy, 2.8-Spain and 2.68-UK. CONCLUSIONS:
This large sample of ACS patients provides additional informa-
tion on important RFs by country and may be useful to construct
country-speciﬁc outcomes models. PCI was most frequently used
in Germany and the number of RFs was highest in Spain.
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Patients (pts) with multiple risk factors of cardiovascular disease
(CVD) are at the supreme priority for preventive cardiology.
Therefore, under the auspices of the Ministry of Health in Poland,
POLKARD-SPOK survey was performed to distinguish risk
factors and describe their current management in relation to pre-
vention of CVD. OBJECTIVES: The purpose of the POLKARD-
SPOK survey was to describe baseline characteristics,
management practices and achievement of therapeutic goals in
subgroups of high risk population of fatal CVD in accordance to
ESC deﬁnition. METHODS: Data from representative sample of
1545 general practitioners, on 31,116 pts (mean age 63 ± 2 years;
48.5% males) with documented CVD or high risk of
atherothrombotic events were randomly selected from out-
patients charts database and surveyed. Both pts and practitioner
questionnaires prospectively collected data on cardiovascular risk
factors, lifestyle, diagnostic procedures and medications applied.
RESULTS: Among studied population prevalence of dyslipidemia
